Ovariektomize Sıçanlarda Liraglutid’in Kalp Fonksiyonları Üzerine Etkisi
Amaç: Glukagon benzeri peptit-1 (GLP-1), enteroendokrin L hücrelerinden salgılanan önemli bir inkretin hormondur. GLP-1 analogları,
diyabet ve obezite tedavisi için kullanılmaktadır. Ovaryan hormonların kardiyovasküler fonksiyonların düzenlenmesinde etkili rol
oynadığı iyi bilinmektedir. Postmenopozal kadınlarda kardiyovasküler hastalık insidansı artar. Bu çalışmanın amacı, yumurtalıkları
alınmış sıçanlarda GLP- 1 analoğu olan liraglutid uygulanmasının kardiyak fonksiyonlar ve kalp dokusu oksidatif stres üzerindeki
etkisini araştırmaktır.
Gereç ve Yöntemler: Çalışmada otuz iki genç dişi Wistar albino sıçan kullanıldı. Denekler rastgele kontrol, liraglutid ile tedavi edilen
kontrol, yumurtalıkları alınan (OVX) ve liraglutid ile tedavi edilen OVX gruplarına ayrıldı. İki aylık dişi sıçanlarda ovariektomi ve sahte
cerrahi işlemler uygulandı. Ovariektomi operasyonundan beş hafta sonra liraglutid tedavisi (150μg/kg, deri altı, 14 gün) başlandı. 14
günlük süre sonunda kalp atım hızı ve kan basıncı ölçümleri yapıldıktan sonra hayvanlar sakrifiye edildi, kahverengi ve beyaz yağ dokusu
ağırlıkları ile kalp dokusu malondialdehit (MDA), indirgenmiş glutatyon (GSH), nitrat, glikojen ve askorbik asit seviyeleri ölçüldü.
Bulgular: Kalp hızı açısından tüm gruplar arasında fark bulunmazken, liraglutid uygulanan gruplarda kan basıncı istatistiksel olarak
anlamlı derecede azaldı. MDA ve askorbik asit seviyeleri tüm gruplar arasında önemli bir değişim gözlenmedi. GSH seviyeleri liraglutid
ile tedavi edilen OVX grubunda arttı. Ovariektomi ile kalp dokusunda nitrat düzeylerinin azaldığı saptandı. Kardiyak glikojen düzeyi
OVX ve liraglutid uygulanan OVX grubunda kontrol grubuna göre artmış olarak bulunmuştur. Liraglutid tedavisi kalpteki nitrat
miktarını kontrol seviyelerinde korudu. Ek olarak, liraglutid uygulaması OVX sıçanlarında retroperitoneal yağ birikimini azalttı.
Sonuç: Sonuçlarımız GLP-1 uygulamasının ovariektominin neden olduğu kan basıncı artışı ve kalp dokusunda azalan GSH seviyelerini
korumada etkili olduğu bulunmuştur. Bu nedenle, GLP-1 analogları, postmenopozal dönemde kan basıncının düzenlenmesinde
potansiyel terapötik ajan olarak kabul edilebilir.
The Effect of Liraglutide on Cardiac Functions in Ovariectomized Rats
Aim: Glucagon-like peptide 1 (GLP-1) is an important incretin hormone secreted from enteroendocrine L cells. GLP-1 analogs are
used for the treatment of diabetes and obesity. Ovarian hormones are well known in playing critical roles in regulating cardiovascular
functions. Cardiovascular disease incidence increases in postmenopausal women. The aim of this study was to investigate the effect of
administration of liraglutide, a GLP 1 analogue, on cardiac function and cardiac tissue oxidative stress in ovariectomized rats.
Material and Methods: Thirty two young female Wistar albino rats were used in the study. Subjects were randomly divided into control,
liraglutide-treated control, ovariectomized (OVX), and liraglutide-treated OVX groups. Ovariectomy and sham surgical procedures were
performed in 2-month-old female rats. Liraglutide treatment (150μg/kg, subcutaneous, 14 days) was started five weeks after the ovariectomy
operation. After measuring the heart rate and blood pressure at the end of the 14-day period, the animals were sacrificed, brown and white
adipose tissue weights, and heart tissue malondialdehyde (MDA), reduced glutathione (GSH), nitrate, glycogen and ascorbic acid levels
were measured.
Results: While there was no difference between all groups in terms of heart rate, blood pressure was statistically significantly decreased
in the liraglutide-administered groups. MDA and ascorbic acid levels did not change significantly between all groups. GSH levels
were increased in the liraglutide-treated OVX group. It was found that the cardiac glycogen level was increased in the OVX group
treated with OVX and liraglutide compared to the control group. Nitral levels in the heart tissue were found to be decreased with
ovarectomy. Liraglutide treatment maintained nitrate levels in the heart at control levels. In addition, liraglutide administration reduced
retroperitoneal fat deposition in OVX rats.
Conclusion: Our results showed that GLP-1 administration was effective in reducing the increased blood pressure due to ovariectomy
and maintaining the decreased GSH level in the heart tissue.. Therefore, GLP-1 analogs can be considered as potential therapeutic agents
in the regulation of blood pressure in the postmenopausal period.
___
- 1. de Fátima Laureano Martins J, Souza-Silva TG, Paula HAA,
Rafael VDC, Sartori SSR, Ferreira CLLF. Yacon-based
product improves intestinal hypertrophy and modulates the
production of glucagon-like peptide-1 in postmenopausal
experimental model. Life Sci. 2022;291:120245.
- 2. Marinho PM, Salomon TB, Andrade AS, Behling CS, Putti
JS, Benfato MS, Hackenhaar FS. The effect of n-3 long-chain
polyunsaturated fatty acids and lipoic acid on the heart in
the ovariectomized rat model of menopause. Free Radic Res.
2019;53(6):669-679.
- 3. Yang XP, Reckelhoff JF. Estrogen, hormonal replacement
therapy and cardiovascular disease. Curr Opin Nephrol
Hypertens. 2011;20:133-138.
- 4. Prokai-Tatrai K, Perjesi P, Rivera-Portalatin NM, Simpkins
JW, Prokai L. Mechanistic investigations on the antioxidant
action of a neuroprotective estrogen derivative. Steroids.
2008;73(3):280-288.
- 5. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress
as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931-
947.
- 6.Castardo-de-Paula JC, de Campos BH, Amorim EDT, da
Silva RV, de Farias CC, Higachi L, Pinge-Filho P, Barbosa DS,
Martins-Pinge MC. Cardiovascular risk and the effect of nitric
oxide synthase inhibition in female rats: The role of estrogen.
Exp Gerontol. 2017;97:38-48.
- 7. Knowlton AA, Lee AR. Estrogen and the cardiovascular
system. Pharmacol Ther. 2012;135(1):54-70.
- 8. Phungphong S, Kijtawornrat A, Wattanapermpool J, Bupha-
Intr T. Improvement in cardiac function of ovariectomized
rats by antioxidant tempol. Free Radic Biol Med. 2020;160:239-
245.
- 9. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs
JB, Nesto RW, Wilson PW, Vasan RS. Impact of glucose
intolerance and insulin resistance on cardiac structure and
function: Sex-related differences in the Framingham Heart
Study. Circulation. 2003;107(3):448-454.
- 10. Bhuiyan MS, Fukunaga K. Characterization of an animal
model of postmenopausal cardiac hypertrophy and novel
mechanisms responsible for cardiac decompensation using
ovariectomized pressure-overloaded rats. Menopause.
2010;17:213-221.
- 11. Shi N, He J, Guo Q, Liu T, Han J. Liraglutide protects against
diabetes mellitus complicated with focal cerebral ischemic
injury by activating mitochondrial ATP-sensitive potassium
channels. Neuroreport. 2019;30(7):479-484.
- 12. Hölscher C. Central effects of GLP-1: New opportunities
for treatments of neurodegenerative diseases. J Endocrinol.
2014;221:T31.
- 13. Yaribeygi H, Farrokhi FR, Abdalla MA, Sathyapalan T, Banach
M, Jamialahmadi T, Sahebkar A. The effects of glucagonlike
peptide-1 receptor agonists and dipeptydilpeptidase-4
inhibitors on blood pressure and cardiovascular complications
in diabetes. J Diabetes Res. 202;2021:6518221.
- 14. Deng C, Cao J, Han J, Li J, Li Z, Shi N, He J. Liraglutide activates
the Nrf2/HO-1 antioxidant pathway and protects brain nerve
cells against cerebral ischemia in diabetic rats. Comput Intell
Neurosci. 2018;2018:3094504.
- 15. Hu SY, Zhang Y, Zhu PJ, Zhou H, Chen YD. Liraglutide
directly protects cardiomyocytes against reperfusion injury
possibly via modulation of intracellular calcium homeostasis.
J Geriatr Cardiol. 2017;14(1):57-66.
- 16. Chen WR, Hu SY, Chen YD, Zhang Y, Qian G, Wang J, Yang
JJ, Wang ZF, Tian F, Ning QX. Effects of liraglutide on left
ventricular function in patients with ST-segment elevation
myocardial infarction undergoing primary percutaneous
coronary intervention. Am Heart J. 2015;170(5):845-854.
- 17. Eid RA, Bin-Meferij MM, El-Kott AF, Eleawa SM, Zaki
MSA, Al-Shraim M, El-Sayed F, Eldeen MA, Alkhateeb MA,
Alharbi SA, Aldera H, Khalil MA. Exendin-4 protects against
myocardial ischemia-reperfusion injury by upregulation
of SIRT1 and SIRT3 and activation of AMPK. J Cardiovasc
Transl Res. 2021;14(4):619-635.
- 18. Yin W, Borniger JC, Wang X, Maguire SM, Munselle ML,
Bezner KS, Tesfamariam HM, Garcia AN, Hofmann HA,
Nelson RJ, Gore AC. Estradiol treatment improves biological
rhythms in a preclinical rat model of menopause. Neurobiol
Aging. 2019;83:1-10.
- 19. Barthem CS, Rossetti CL, Carvalho DP, da-Silva WS. Metformin
ameliorates body mass gain and early metabolic changes in
ovariectomized rats. Endocr Connect. 2019;8(12):1568-1578.
- 20. Model JFA, Lima MV, Ohlweiler R, Lopes Vogt É, Rocha
DS, Souza SK, Türck P, Araújo ASDR, Vinagre AS.
Liraglutide improves lipid and carbohydrate metabolism of
ovariectomized rats. Mol Cell Endocrinol. 2021;524:111158.
- 21. Kim JH, Cho HT, Kim YJ. The role of estrogen in adipose tissue
metabolism: Insights into glucose homeostasis regulation.
Endocr J. 2014;61(11):1055-1067.
- 22. Casini AF, Ferrali M, Pompella A, Maellaro E, Comporti
M. Lipid peroxidation and cellular damage in extrahepatic
tissues of bromobenzene-intoxicated mice. Am J Pathol.
1986;123(3):520-531.
- 23. Aykac G, Uysal M, Yalçın AS, Kocak-Toker N, Sivas A, Oz
H. The effect of chronic ethanol ingestion on hepatic lipid
peroxide, glutathione, glutathione peroxidase and glutathione
transferase in rats. Toxicology. 1986;36:71-76.
- 24. Miranda KM, Espey MG, Wink DA. A rapid simple
spectrofotometric method for simultaneous detection of
nitrate and nitrite. Nitric Oxide. 2001;5(1):62-71.
- 25. Berger J, Shepard D, Morrow F, Taylor A. Relationship between
dietary intake and tissue levels of reduced and total vitamin C
in the nonscorbutic guinea pig. J Nutr. 1989;119:734-740.
- 26. Bendale DS, Karpe PA, Chhabra R, Shete SP, Shah H, Tikoo K.
17-β Oestradiol prevents cardiovascular dysfunction in postmenopausal
metabolic syndrome by affecting SIRT1/AMPK/
H3 acetylation. Br J Pharmacol. 2013;170(4):779-795.
- 27. Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, Seon HJ, Kim
KS. Cardioprotective effects of exenatide in patients with STsegment-
elevation myocardial infarction undergoing primary
percutaneous coronary intervention: Results of exenatide
myocardial protection in revascularization study. Arterioscler
Thromb Vasc Biol. 2013;33(9):2252-2260.
- 28. Gortan Cappellari G, Losurdo P, Mazzucco S, Panizon E,
Jevnicar M, Macaluso L, Fabris B, Barazzoni R, Biolo G,
Carretta R, Zanetti M. Treatment with n-3 polyunsaturated
fatty acids reverses endothelial dysfunction and oxidative stress
in experimental menopause. J Nutr Biochem. 2013;24(1):371-
379.
- 29. Wu H, Xiao C, Zhao Y, Yin H, Yu M. Liraglutide Improves
Endothelial Function via the mTOR Signaling Pathway. J
Diabetes Res. 2021;2021:2936667.
- 30. Aung MM, Slade K, Freeman LAR, Kos K, Whatmore JL,
Shore AC, Gooding KM. Locally delivered GLP-1 analogues
liraglutide and exenatide enhance microvascular perfusion in
individuals with and without type 2 diabetes. Diabetologia.
2019;62(9):1701-1711.
- 31. Han L, Yu Y, Sun X, Wang B. Exendin-4 directly improves
endothelial dysfunction in isolated aortas from obese rats
through the cAMP or AMPK-eNOS pathways. Diabetes Res
Clin Pract. 2012;97(3):453-460.
- 32. DeNicola M, Du J, Wang Z, Yano N, Zhang L, Wang Y, Qin
G, Zhuang S, Zhao TC. Stimulation of glucagon-like peptide-1
receptor through exendin-4 preserves myocardial performance
and prevents cardiac remodeling in infarcted myocardium.
Am J Physiol Endocrinol Metab. 2014;307(8):E630-643.
- 33. Chang G, Zhang P, Ye L, Lu K, Wang Y, Duan Q, Zheng A,
Qin S, Zhang D. Protective effects of sitagliptin on myocardial
injury and cardiac function in an ischemia/reperfusion rat
model. Eur J Pharmacol. 2013;718(1-3):105-113.
- 34. Chinda K, Chattipakorn S, Chattipakorn N. Cardioprotective
effects of incretin during ischaemia-reperfusion. Diab Vasc
Dis Res. 2012;9:256-269.
- 35. Simanenkova A, Minasian S, Karonova T, Vlasov T, Timkina
N, Shpilevaya O, Khalzova A, Shimshilashvili A, Timofeeva
V, Samsonov D, Borshchev Y, Galagudza M. Comparative
evaluation of metformin and liraglutide cardioprotective
effect in rats with impaired glucose tolerance. Sci Rep.
2021;11(1):6700.
- 36. Guan G, Zhang J, Liu S, Huang W, Gong Y, Gu X. Glucagonlike
peptide-1 attenuates endoplasmic reticulum stressinduced
apoptosis in H9c2 cardiomyocytes during hypoxia/
reoxygenation through the GLP-1R/PI3K/Akt pathways.
Naunyn Schmiedebergs Arch Pharmacol. 2019;392(6):715-
722.
- 37. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R,
Zourelias L, Stolarski C, Shen YT, Shannon RP. Recombinant
glucagon-like peptide-1 increases myocardial glucose uptake
and improves left ventricular performance in conscious dogs
with pacing-induced dilated cardiomyopathy. Circulation.
2004;110(8):955-961.
- 38. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular
actions of the incretin hormone glucagon-like peptide-1:
Potential therapeutic benefits beyond glycaemic control? Br J
Pharmacol. 2009;157(8):1340-1351.
- 39. Chien CT, Jou MJ, Cheng TY, Yang CH, Yu TY, Li PC.
Exendin-4-loaded PLGA microspheres relieve cerebral
ischemia/reperfusion injury and neurologic deficits through
long-lasting bioactivity-mediated phosphorylated Akt/eNOS
signaling in rats. J Cereb Blood Flow Metab. 2015;35(11):1790-
1803.
- 40. Li PC, Liu LF, Jou MJ, Wang HK. The GLP-1 receptor
agonists exendin-4 and liraglutide alleviate oxidative stress
and cognitive and micturition deficits induced by middle
cerebral artery occlusion in diabetic mice. BMC Neurosci.
2016;17(1):37.
- 41. Cui X, Liang H, Hao C, Jing X. Liraglutide preconditioning
attenuates myocardial ischemia/ reperfusion injury via homer1
activation. Aging. (Albany NY) 2021;13(5):6625-6633.
- 42. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ,
Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ.
GLP-1R agonist liraglutide activates cytoprotective pathways
and improves outcomes after experimental myocardial
infarction in mice. Diabetes. 2009;58(4):975-983.
- 43. Nakatani Y, Kawabe A, Matsumura M, Aso Y, Yasu T,
Banba N, Nakamoto T. Effects of GLP-1 receptor agonists
on heart rate and the autonomic nervous system using holter
electrocardiography and power spectrum analysis of heart rate
variability. Diabetes Care. 2016;39(2):e22-23.
- 44. Kaur A, Negi P, Sarna V, Prasad R, Chavan BS, Malhotra A,
Kaur G. The appraisement of antioxidant and oxidant status
in women undergoing surgical menopause. Indian J Clin
Biochem. 2017;32(2):179-185.
- 45. Machi JF, Dias Dda S, Freitas SC, de Moraes OA, da Silva
MB, Cruz PL, Mostarda C, Salemi VM, Morris M, De Angelis
K, Irigoyen MC. Impact of aging on cardiac function in a
female rat model of menopause: Role of autonomic control,
inflammation, and oxidative stress. Clin Interv Aging.
2016;11:341-350.
- 46. Hussein AM, Eid EA, Taha M, Elshazli RM, Bedir RF, Lashin
LS. Comparative study of the effects of GLP1 analog and
SGLT2 inhibitor against diabetic cardiomyopathy in type 2
diabetic rats: Possible underlying mechanisms. Biomedicines.
2020;8(3):43.
- 47. Abdelsameea AA, Abbas NA, Abdel Raouf SM. Liraglutide
attenuates partial warm ischemia-reperfusion injury
in rat livers. Naunyn Schmiedebergs Arch Pharmacol.
2017;390(3):311-319.
- 48. Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide
for the treatment of obesity. Trends Cardiovasc Med.
2021;21:S1050-1738(21)00158-4.